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Abbreviations 
 
aa amino acid 
AIDS Acquired Immune Deficiency Syndrom 
Amp ampicillin 
CBP calmodulin-binding protein 
CCR chemokine receptor for CC chemokines  
CD cluster of differentiation 
CHR C-terminal helix region 
CTL cytotoxic T-cells 
CXCR chemokine receptor for CXC-
chemokines  
ddH2O Aqua bidest 
DNA Desoxyribonucleinacid 
E.coli Escherichia coli 
ELISA enzyme linked immunosorbent assay 
Env envelope protein 
Fab fragment antigen binding  
FeLV feline leukemia virus 
FIV Feline Immune Deficiency Virus  
FCS fetal calf serum 
ffu/ml focus forming units per milliliter 
FP fusion peptide 
Gag group specific antigen 
HAART highly active anti retroviral therapy 
HAT hypoxanthine-aminopterin-thymine 
HIV human immune deficiency virus 
HTLV human T cell leukemia virus 
Ig immunglobuline 
IN Integrase 
kA association constant 
kD dissociation constant 
kB kilo base 
kD kilo Dalton 
LTR long terminal repeat 
MCS multiple cloning site 
MHC major histocompatibility complex 
MVA modified vaccinia Ankara virus 
Nef negative factor 
NHR N-terminal helix region 
NIAID National Institute of Allergy and  
Infectious Diseases 
NIH National Institute of Health 
NMR nuclear magentic resonance,  





PCR polymerase chain reaction 
PEG poly ethylene glycol 




RT Reverse transcriptase 
SCID severe combined immune deficiency 
SHIV SIV-HIV-hybride viruses 
SIV Simian Immune Deficiency Virus 
Tat Transactivator of transcription  
TM transmembrane region 
UNAIDS United Nations Department of AIDS 
Vif virion infectivity factor 
WHO World Health Organisation 
wt Wildtyp 
 




















X optional amino acid 
Y Tyrosin 
 
Bases of nucleotide sequences: 
A Adenin 
C Cytosin 
G Guanin 
T Thymin 
 
 
 
